The global Non-Sterile Liquids/Suspensions Market held a valuation of USD 2.6 Billion in 2022, and it is further projected to expand at a CAGR of 6.5% over the forecasted years. According to a recent study by Future Market Insights, the oral dosage form is leading the market with a share of about 29.5% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 2.6 Billion |
| Market Value 2033 | USD 5.2 Billion |
| CAGR 2023 to 2033 | 6.5% |
| Market Share of Top 5 Countries | 53.0% |
| Key Market Players | AbbVie Pharmaceutical Contract Manufacturing, Aenova Group, APPCO Pharmaceutical Corporation, Atral Pharmaceutical, Aurigene Pharmaceutical Services (Dr. Reddy’s), Biological E. Ltd., BioPlus Life Sciences, Bora Pharmaceuticals, Cambrex Corporation, COC Farmaceutici, Contract Pharmaceuticals Limited (CPL), DPT Laboratories, Ltd., Eurofins, JGL d.d., Mikart, PharmaVision (Vizyon Holding), Pierre Fabre, TriRx Pharmaceutical Services, UI Pharmaceuticals, Wasdell Group, Aphena Pharma, and Syngene International |
Active pharmaceutical ingredients (API) are dissolved in aqueous and non-aqueous solvents, suspended in suitable media, or incorporated into oil or water phases to create liquid dosage forms.
As a result, there are many different formulations of pharmaceutical liquids. Liquids that are not sterile are prepared in settings that are clean but not entirely sterile. These non-sterile liquid pharmaceuticals can be applied internally or externally.
An oral or topical route of drug administration can be used to provide a non-sterile liquid dose form. Moreover, liquid dosage forms provide advantages over other specialized dosage forms, including better patient compliance, quicker absorption, and more dosing flexibility.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 6.5% between 2023 and 2033, owing to the various applications in a wide range of medication formulations.
The demand for these products is increasing with respect to the pediatric and geriatric formulations and apart from this, the convenience and compliance provided by the products like mouth washes, gels, creams in reference to the way they are applied or consumed is something which fuels the growth of this market.
The global market holds around 7.3% share of the overall global solvent market with a value of around USD 35.6 Billion, in 2022.
Non-sterile liquids/suspensions can be used to deliver a variety of medications, including prescription drugs, non-prescription drugs, vitamins, dietary supplements, and nutraceuticals. As the population ages, there is a growing demand for formulations that address the specific needs of the elderly. Pediatric formulations are also gaining traction, driven by the need for dosage forms that are easier to administer in children, example oral dosage forms.
Pharmaceutical formulations, such as oral syrups, cough medicines, and other liquid drugs, frequently contain non-sterile liquids and suspensions. The demand for medicines may be influenced by the expanding access to healthcare in emerging nations, the rising prevalence of chronic diseases, and the expanding use of non-sterile fluids or suspensions.
It is also typical practice to produce nutraceuticals and nutritional supplements, such as vitamins, minerals, and botanical extracts, using non-sterile liquid or suspension formulations. The demand for non-sterile liquid or suspension formulations in this sector may rise as a result of rising consumer knowledge of the advantages of nutraceuticals and dietary supplements for health and wellness.
The aforementioned factors are expected to cause the global market to expand swiftly and reach an estimated value of USD 5.2 Billion in 2033.
Due to ease of administration, better taste, and easier swallowing, many consumers, especially kids and elderly patients, may choose liquid formulations over solid dose forms like tablets or capsules. This can result in a rise in demand for non-sterile suspension or liquid formulations. This growing preference of liquid formulations would present lucrative opportunities for the market in the coming years.
Moreover, the creation of non-sterile liquids or suspensions with improved drug stability, bioavailability, and therapeutic efficacy may be made possible by the development of innovative drug delivery technologies like nanotechnology, liposomes, and microencapsulation.
The market for non-sterile liquid or suspension formulations may be stimulated by these developments. In fact, companies today are utilizing cutting-edge technologies to improve both patient compliance and the bioavailability of dose forms.
Principal Consultant
Non-sterile liquid or suspension formulations may need to adhere to stringent regulatory criteria, such as those for quality assurance, safety, labeling, and manufacturing procedures. The market may be constrained by meeting these legal standards because they can be time-consuming and expensive, especially for startups or smaller firms.
Other than this, in comparison to solid dosage forms, non-sterile liquids or suspensions may have a shorter shelf life because they may be more prone to deterioration, microbial development, and other stability issues. This could shorten the shelf life of non-sterile liquid or suspension items, which might lead to product waste and higher expenditures for product expiry or recalls.
The USA dominated the North American region with market share of around 23.3% in the global market in 2022.
The USA market for non-sterile liquids/suspensions is driven by several factors, including the increasing demand for oral and topical dosage forms, the need for customized solutions that are designed for palatability and patient compliance, and the cost-effectiveness of non-sterile formulations compared to sterile formulations.
The USA market is characterized by a high level of innovation and technological advancement, which drives the development of new and improved non-sterile liquid/suspension formulations. The use of advanced technologies such as nanotechnology, microencapsulation, and spray drying can improve the stability, bioavailability, and efficacy of non-sterile liquid/suspension formulations.
Germany held a market share of 4.9% in 2022 in the global market. Non-sterile liquids/suspensions are frequently used to treat a variety of medical conditions such as cough, cold, allergies, and pain relief. The rising demand for OTC medications is propelling this market forward in this region.
With a focus on enhancing the patient experience and medication adherence, there is an increasing emphasis on patient-centric treatment in Germany. Non-sterile liquid or suspension formulations may have benefits for patients in terms of dosing flexibility, ease of administration, and patient convenience, all of which are consistent with patient-centric care paradigms.
The elderly population in Germany may have particular demands and preferences when it comes to the administration of medications. Older adults who may have trouble swallowing pills or capsules may prefer non-sterile liquid or suspension forms, which could increase demand for these formulations.
India had a market share of 8.8% in the global market in 2022. India's population is large and growing, which is driving demand for non-sterile liquids/suspensions. Chronic diseases such as diabetes, cardiovascular disease, and cancer are becoming more common in India.
With a population of over 1.3 Billion people, India has a high demand for pharmaceutical products, including non-sterile liquids/suspensions. The increasing population and urbanization in India have led to a rise in the prevalence of diseases and health conditions, which has increased the demand for medications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The oral dosage form held a market share of 29.5% in the global market in 2022.
For patients who might have trouble swallowing solid dosage forms like pills or capsules, non-sterile liquid or suspension formulations are frequently simple to administer. They are thus especially well-suited for certain patient groups, including kids, the elderly, and people who have trouble swallowing or who have other medical issues that make it difficult to take solid dosage forms.
Many patients prefer liquid or suspension formulations due to their ease of use, convenience, and familiarity. This can contribute to the wide acceptance of oral dosage forms in the non-sterile liquid or suspensions market, as patient preference and convenience are important factors in medication selection and adherence.
The human medication segment held a market share of 40.1% in the global market in 2022. It is expected to expand due to technological advancements in disease diagnosis and treatment and increasing human populations with various acute diseases like acute pain and cold symptoms, and chronic diseases like cancer and diabetes. This further increases the adoption of pharmaceutical medicines.
Overall, the use of non-sterile liquids/suspensions in human medication offers advantages like enhanced bioavailability, rapid onset of action, improved medication adherence, and flexible dosing, thus driving the global market.
Pharmaceutical companies held a market share of 33.1% in the year 2022. Pharmaceutical companies are using more non-sterile liquids/suspensions in the production of medications due to the various advantages associated with formulations in human medications and veterinary medications.
Pharmaceutical companies are taking non-sterile liquids/suspensions in bulk or package form for various applications like various dosage formulations with parenteral as well for rinsing of equipment. Apart from this, the rising number of pharmaceutical companies around the globe is another point as to which it dominates this segment.
Key players are focusing on agreements, mergers, partnerships, collaborations, and acquisitions as well as the introduction and commercialization of novel products and pharmaceuticals in order to broaden their clientele and raise business income. A few examples of strategies acquired by the key players:
Similarly, recent developments related to non-sterile liquids/suspensions market has been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2023 to 2033 |
| Forecast Period | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | USA, Canada, Mexico, Brazil, Argentina, United Kingdom., Germany, Italy, Spain, France, Russia, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, and South Africa |
| Key Market Segments Covered | Dosage Form, Application, End User, and Region |
| Key Companies Profiled | AbbVie Pharmaceutical Contract Manufacturing; Aenova Group; APPCO Pharmaceutical Corporation; Atral Pharmaceutical; Aurigene Pharmaceutical Services (Dr. Reddy’s); Biological E. Ltd.; BioPlus Life Sciences; Bora Pharmaceuticals; Cambrex Corporation; COC Farmaceutici; Contract Pharmaceuticals Limited (CPL); DPT Laboratories, Ltd.; Eurofins; JGL d.d.; Mikart; PharmaVision (Vizyon Holding); Pierre Fabre; TriRx Pharmaceutical Services; UI Pharmaceuticals; Wasdell Group; Aphena Pharma; Syngene International |
| Pricing | Available upon Request |
From 2018 to 2022, the market registered a CAGR of 7.3%.
The market is estimated to reach USD 5.2 billion by 2033.
Human medication hold high revenue potential.
The United States, Japan, and the United Kingdom dominate the global market.
The market is forecast to register a CAGR of 6.5% through 2033.
1. Executive Summary | Non-Sterile Liquids/Suspensions Market 2. Market Overview 3. Key Market Trends 4. Value-Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Dosage Form 7.1. Oral 7.1.1. Mixtures 7.1.2. Linctures 7.1.3. Syrups 7.1.4. Elixirs 7.1.5. Mouth Washes/Gargles 7.1.6. Drops 7.2. Ear & Eye 7.2.1. Drops 7.2.2. Lotions 7.3. Nasal 7.3.1. Drops 7.3.2. Sprays 7.4. Topical 7.4.1. Gel 7.4.2. Creams 7.5. Parenteral 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application 8.1. Human Medication 8.2. Nutraceuticals 8.3. Cosmetics 8.4. Medical Devices 8.5. Veterinary Health 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 9.1. CMO/CDMO 9.2. Pharmaceutical Companies 9.2.1. Human 9.2.2. Veterinary 9.3. Cosmeceutical Companies 9.4. Nutraceutical Companies 9.5. Medical Device Manufacturers 9.6. Others 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. Middle East and Africa (MEA) 11. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 12. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17. Middle East and Africa (MEA) Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. AbbVie Pharmaceutical Contract Manufacturing 19.2. Aenova Group 19.3. APPCO Pharmaceutical Corporation 19.4. Atral Pharmaceutical 19.5. Aurigene Pharmaceutical Services (Dr. Reddy’s) 19.6. Biological E. Ltd. 19.7. BioPlus Life Sciences 19.8. Bora Pharmaceuticals 19.9. Cambrex Corporation 19.10. COC Farmaceutici 19.11. Contract Pharmaceuticals Limited (CPL) 19.12. DPT Laboratories, Ltd. 19.13. Eurofins 19.14. JGL d.d. 19.15. Mikart 19.16. PharmaVision (Vizyon Holding) 19.17. Pierre Fabre 19.18. TriRx Pharmaceutical Services 19.19. UI Pharmaceuticals 19.20. Wasdell Group 19.21. Aphena Pharma 19.22. Syngene International 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Non-Sterile Liquids/Suspensions Market
